BioNTech Completes CureVac Acquisition, Expanding Its mRNA Platform

BioNTech SE ( NASDAQ: BNTX) has completed its acquisition of CureVac N.V., closing its public exchange offer and moving toward full integration of the two mRNA pioneers. The transaction brings CureVac’s technology and manufacturing capabilities under BioNTech’s umbrella, strengthening BioNTech’s position in the rapidly evolving messenger RNA (mRNA) field.

As part of the offer, approximately 86.75% of CureVac’s outstanding shares were tendered in exchange for BioNTech American Depositary Shares. BioNTech plans to complete a compulsory acquisition of the remaining shares in early 2026, after which CureVac will become a wholly owned subsidiary.

Combining Complementary mRNA Capabilities

The acquisition is designed to enhance BioNTech’s end-to-end mRNA capabilities, including mRNA design, delivery technologies, and manufacturing scale. CureVac’s research expertise and production infrastructure complement BioNTech’s established platform, which spans vaccines, oncology programs, and next-generation immunotherapies.

BioNTech expects the combined capabilities to support continued development of mRNA-based cancer treatments as well as other therapeutic applications.

Integration and Next Steps

CureVac will continue operating under its existing organizational structure while BioNTech conducts a detailed review of scientific, operational, and strategic priorities. Current management teams will remain in place during this transition period as longer-term integration plans are finalized.

Broader Context

By bringing together two early leaders in mRNA technology, BioNTech aims to accelerate innovation and strengthen its long-term position in a field that continues to expand beyond infectious disease vaccines into oncology and other areas of medicine.